Blog

Beyond the Manuscript Evrima Chicago

NAPERVILLE, IL / ACCESS Newswire / September 24, 2025 /

Kaye Allene Allen: Faith, Resilience, and Speaking to the Next Generation

Introduction: A Voice Born Out of Trial

When an author writes after crisis, the words are never just words. They are survival, testimony, and offering. For Kaye Allene Allen, the manuscript What Does He Say to the Next Generation is not merely a book. It is the vineyard she never expected to plant, sown after a stroke reshaped her body, her ministry, and her sense of purpose.

The Calling Behind the Pages

Allen frames her story with candor. Before illness, she was a pastor, teacher, and women’s ministry leader. After illness, she felt stripped of assignment and identity until prayer, scripture, and memory recalled her to a new form of ministry: discipling the young.

Where some might see a setback, Allen saw a summons. Her book, written as a series of structured lessons, is a way of pouring spiritual inheritance into a generation facing distraction, anxiety, and fractured cultural signals.

Lessons as Blueprints for Character

Each chapter in Allen’s book functions less as abstract theology and more as apprenticeship in living.

• Obedience is framed not as blind compliance but as building life on a rock-solid foundation.

• Prayer is not ritual recitation but light in the darkness of overwhelm.

• The Fruits of the Spirit become virtues tested not in theory but in cafeterias, friendships, and late-night decisions.

• Forgiveness, trust, patience, and truth are presented in language young readers can practice, memorize, and carry into their daily battles.

Allen’s pedagogy is deliberate: memorize scripture, apply it, reflect on it, pray it, and write about it. Each lesson is scaffolded with reflection questions and journal space, anchoring learning not in passive reading but in lived practice.

The Vineyard Metaphor

When Allen speaks of her “vineyard,” she is invoking Jeremiah’s imagery of rebuilding and fruit-bearing. Her vineyard is not soil and vine, but classroom and heart. By focusing on the next generation, she aligns herself with the ancient mandate of Titus 2 – that older women and men disciple the young, passing wisdom not through abstract sermons but through lived mentorship.

Why This Work Matters

In a moment when American youth culture is shaped by fragmented digital voices, Allen’s text stands as a counter-narrative. It is a manual of rootedness. More than that, it represents a transfer of spiritual capital: the hard-won lessons of an elder poured into the fragile vessels of the young.

Her book reminds us that manuscripts are not just records. They are inheritances. And in this case, inheritance is not wealth or property, but instruction, discipline, and encouragement.

Beyond the Manuscript

What makes Allen a fit for our Beyond the Manuscript series is that her book is not simply literature. It is lived theology. Born of physical limitation, it teaches spiritual resilience. Written for children and youth, it models intergenerational responsibility.

In Allen’s case, the manuscript itself is only the beginning. Each verse memorized, each prayer written in a journal, each child mentored becomes a continuation of the text. Her vineyard grows not in pages but in people.

Conclusion: From Stroke to Seed

If every manuscript carries both a story and a purpose, What Does He Say to the Next Generation carries Allen’s renewed purpose after loss. It is her answer to the question, “Lord, what now?”

For Evrima Chicago, highlighting Allen’s journey is to remind readers of what Beyond the Manuscript stands for: that the most powerful manuscripts are not only read but lived. And that sometimes, the fruit of a book is not found on shelves, but in lives transformed.

Disclaimer

• This is a critical, opinion-based cultural analysis authored by the Editorial Team and reflects their personal editorial perspective.

• The views expressed do not represent the institutional stance of Evrima Chicago.

• The article draws from open-source information, legal filings, published interviews, and public commentary.

• All allegations referenced remain under investigation or unproven in a court of law.

• No conclusion of criminal liability or civil guilt is implied.

• Any parallels made to public figures are interpretive in nature and intended to examine systemic patterns of influence, celebrity, and accountability in American culture.

• Where relevant, satirical, rhetorical, and speculative language is used to explore public narratives and their societal impact.

• Readers are strongly encouraged to engage critically and examine primary sources where possible.

• This piece is protected under the First Amendment of the U.S. Constitution and published under recognized standards of opinion journalism.

• Editorial inputs contact: waasay@evrimachicago.com

• Evrima Chicago remains committed to a clear distinction between fact-based reporting and individual editorial perspective.

PR & Media Contact
Dan Wasserman
pr@evrimachicago.com

SOURCE: Kaye Allene Allen

View the original press release on ACCESS Newswire

ATLANTA, GA / ACCESS Newswire / September 25, 2025 / QumulusAI, a provider of GPU-powered cloud infrastructure for artificial intelligence, today announced the appointment of Michael Maniscalco as Chief Executive Officer to propel the company through a rapid growth phase.

Maniscalco, formerly CTO of Applied Digital, brings deep expertise in scaling high-performance computing platforms – under his leadership at Applied Digital, his team deployed 6,000 state-of-the-art GPUs in 12 months. At QumulusAI, he will drive expansion of the company’s differentiated approach of owning the full stack – from energy and data centers to GPU-accelerated cloud services – delivering cost-efficient, enterprise-grade AI infrastructure with the speed to move fast and the scale to grow with customers.

The company also announced two additional executive appointments: Ryan DiRocco as Chief Technology Officer and Stephen Hunton as Chief Marketing Officer. DiRocco, previously CTO at Performive LLC, a leading VMware-focused managed multicloud provider. In this role, he will oversee QumulusAI’s technical strategy, ensuring products are secure, high-performing, and aligned with customer needs, while guiding clients’ smooth, cost-effective adoption of AI.

Hunton, who most recently served as Head of Global Social and Content Experience at IBM, adds global marketing expertise from Google, YouTube and Chevrolet. In this role, Hunton will focus on establishing the brand as the category leader in AI infrastructure – driving market visibility, accelerating enterprise adoption, and building the momentum that will fuel long-term value for customers and partners/investors.

The strengthened leadership team will focus on expanding market presence, accelerating product innovation, and building strategic partnerships as QumulusAI advances its mission to make enterprise-grade AI supercomputing more accessible.

“These appointments mark a pivotal inflection point for QumulusAI,” said Steve Gertz, Chairman of the Board. “AI adoption is accelerating across every industry, and the ability to deliver scalable, cost-efficient infrastructure has become a critical enabler. Michael, Ryan, and Stephen bring proven expertise in building technology platforms, scaling infrastructure, and creating global brands. This team has the vision and execution experience needed to establish QumulusAI as a premier AI infrastructure provider.”

“The demand for scalable AI infrastructure is one of the fastest-growing markets in tech,” said Steven Dickens, CEO & Principal Analyst at HyperFrame Research. “QumulusAI’s model of controlling the full stack positions it to deliver performance and economics that many enterprises simply can’t get from hyperscalers. Adding Michael Maniscalco as CEO is a strong signal the company is ready to scale.”

About QumulusAI

QumulusAI is a vertically integrated AI infrastructure company building the most resilient distributed AI cloud, by innovating around power, data center and GPU-based cloud services-the company delivers access at hyperspeed to high-performance computing with enhanced cost control, reliability, and flexibility. Machine learning teams, AI startups, research institutions, and growing enterprises can now scale their AI training and inference workloads quickly and cost effectively.

For more information, visit https://www.qumulusai.com

Press: media@qumulusai.com

Investors: investors@qumulusai.com

Follow QumulusAI on social media: https://www.linkedin.com/company/qumulusai

SOURCE: QumulusAI

View the original press release on ACCESS Newswire

Mentavi’s clinically validated, asynchronous ADHD assessment – recently published in the Journal of Clinical Psychiatry – shortens wait times from months to days and empowers students to access timely support.

GRAND RAPIDS, MICHIGAN / ACCESS Newswire / September 25, 2025 / As the back-to-school season begins, the strain of transition extends beyond students to parents, professors, and staff. Limited campus resources often mean long waits for ADHD, anxiety, or depression evaluations, delaying care and harming academic performance.

Mentavi Health‘s clinically validated, asynchronous Diagnostic Evaluation – the first online assessment for adult ADHD validated against the current standard of care and now peer-reviewed and published in the Journal of Clinical Psychiatry – reduces waits from weeks to days, giving students timely answers when they matter most.

“Early identification and treatment of ADHD and related mental health conditions is crucial for improved clinical outcomes,” said Mentavi Health Chief Medical Officer Barry K. Herman, M.D., MMM. “Timely diagnosis allows students to access the right accommodations and support to stay on track academically and personally.”

Mentavi now serves more than a dozen higher-education institutions nationwide and has completed over 20,000 student evaluations, demonstrating both the scalability of its services and the value institutions place on timely, validated mental health support. Publication in the Journal of Clinical Psychiatry, one of the field’s leading peer-reviewed journals, further underscores Mentavi’s commitment to scientific rigor and expanding evidence-based access to care.

“For many of our students, the greatest challenge isn’t the classroom itself but the invisible barriers that prevent them from accessing the accommodations they are entitled to under federal law,” said Jana Garnett, DSPS Coordinator/Director at Santa Barbara City College. “By making professional diagnoses accessible and affordable, Mentavi gives our students a pathway to the support they need to persist and succeed in college.”

Efficient and affordable support

Students can complete the Diagnostic Evaluation independently in one to two hours. Each evaluation is reviewed by a licensed, doctorate-level clinician – not automated AI – with results delivered within five days. Students may then share their results with the appropriate offices at their college or university to discuss accommodations or treatment options when warranted. 

Alternatively, in over 40 states, students can choose to meet with a Mentavi clinician to explore therapy, medical treatment, or coaching. This flexibility allows institutions to either keep students within their own health systems or to expand support through Mentavi’s nationwide network. At $189 per evaluation, Mentavi’s service is also far more affordable than traditional in-clinic assessments.

Improved student outcomes and institutional reputation

Early and accurate diagnosis empowers students to understand their challenges, access the right support, and adopt strategies that improve performance, strengthen retention, and build adaptability for life after graduation. For institutions, providing timely answers demonstrates a commitment to student well-being and reduces the risk of students falling behind.

“With national discussions underway about stimulant and non-stimulant treatments, and with increasing state-level scrutiny of AI in healthcare, Mentavi stands out by combining validated assessments with a human-centered model: every evaluation is reviewed by a licensed clinician, ensuring accuracy and accountability,” said Keith Brophy, CEO of Mentavi Health.

“Our mission has always been to make clinically validated mental health care accessible and affordable. As the new school year begins, higher-education institutions seek proven ways to support their students while managing limited resources. By partnering with Mentavi, colleges and universities can offer timely, evidence-based diagnosis and care as appropriate that reduces the stress families, faculty, and staff feel during this critical transition period.”

For more information, visit Mentavi Health or ADHD Online. The Mentavi Health Diagnostic Evaluation is clinically validated for the diagnosis of ADHD in adults. Study results were published in the Journal of Clinical Psychiatry on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).

About Mentavi Health and ADHD Online

Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Mental Health Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, compliant online mental health care. For more information, visit mentavi.com.

Media contact:

Tim Cox, ZingPR for Mentavi Health
tim@zingpr.com

SOURCE: Mentavi Health

Related Images

View the original press release on ACCESS Newswire

Existing investors Battery Ventures, Left Lane Capital, and M-Fund also joined to fuel Fetcherr’s global growth and cross-industry expansion

TEL AVIV, IL / ACCESS Newswire / September 25, 2025 / Fetcherr, a pioneer in generative AI for strategic decision-making, today announced the closing of a $42 million Series C funding round led by Salesforce Ventures. Previous investors Battery Ventures, Left Lane Capital and M-Fund also participated, signaling continued confidence in Fetcherr’s category-defining performance and vision to transform the travel sector and beyond.

“Fetcherr has established itself as an essential revenue driver and a turnkey technology partner for some of the world’s leading airlines,” said Roy Cohen, Co-Founder and CEO of Fetcherr. “We’re thrilled to welcome Salesforce Ventures as a growth partner. With the support of our investors, we’re set to expand beyond aviation and into other legacy sectors where real-time, data-driven decision-making is long overdue.”

Fetcherr is the industry’s first AI-native market engine designed to understand complex market dynamics, forecast demand, and generate real-time pricing, inventory and resource management decisions based on predicted market behavior across all variables. Fetcherr’s proprietary system, anchored by its Large Market Model (LMM), has already delivered significant impact for airline partners by enabling granular, predictive pricing that responds instantly to market demand.

“Industries across the board are undergoing seismic shifts with AI – the need for intelligent, automated systems isn’t optional, it’s more critical than ever,” said Nowi Kallen, Managing Director at Salesforce Ventures. “Fetcherr’s AI platform is expanding the possibilities of generative AI for enterprises still dependent on outdated logic and forecasting. We look forward to supporting their next chapter of global growth and expansion into new domains.”

The new capital will accelerate Fetcherr’s ongoing growth trajectory as it enters new international markets and industries, earning its place among next-generation technology leaders reshaping enterprise infrastructure. Airlines already using Fetcherr’s technology can make automated, insight-backed micro and macro decisions, powered by multi-dimensional views of the global market and economy. A growing partner network, including Delta Air Lines, Virgin Atlantic, WestJet, Viva Aerobus and Azul, underscores Fetcherr’s rapid rise and potential across industries.

About Fetcherr

Fetcherr is a generative AI company that has developed a unique, AI-driven market engine. Its proprietary Large Market Model (LMM) revolutionizes business decision-making by generating real-time market insights from diverse data sources and seamlessly executing critical business decisions through its advanced AI architecture. Built on deep learning principles, Fetcherr’s transparent approach offers explainable insights for predictive pricing, inventory management, and resource optimization. This secure, cloud-based, and seamless solution integrates easily with existing infrastructure, reducing IT overhead and enabling swift adoption. Fetcherr disrupts traditional, rule-based revenue systems, leveraging deep learning to position businesses to become next-generation, AI-driven organizations. For more information, please visit www.fetcherr.io.

Media Contact
fetcherr@5wpr.com

SOURCE: Fetcherr

View the original press release on ACCESS Newswire

AFM rebrand highlights private-label expertise, expanded global reach, and complete solutions for water, food & beverage, pharmaceutical, and industrial markets.

RENSSELAER, IN / ACCESS Newswire / September 25, 2025 / American Meltblown & Filtration, Inc. (AMBF) announced today it will officially change its name to American Filter Manufacturing Inc. (AFM), effective October 1, 2025. The new name reflects the company’s evolution from a meltblown cartridge specialist into a large-scale filtration manufacturer with one of the most complete product lines in the industry.

Founded in 2011, AFM has built its reputation on “Filtration Without Compromise”, delivering solutions that protect water, processes, and people worldwide. Operating from a 148,000 sq. ft. U.S. facility with over 100 employees, AFM manufactures meltblown, pleated, string-wound, high-flow, carbon, and membrane cartridges.

As part of AFM’s commitment to having the most complete product line, its sister company, Liquid Filter Housings, Inc. (LFH) will merge into AFM. Continuing to operate as Liquid Filter Housings, it supplies the industry’s most durable liquid filtration housings solutions. Together, AFM and LFH deliver a complete filtration solution-cartridges, medias, and housings engineered to work seamlessly as one system.

AFM specializes in private-label manufacturing, controlling every step of production – from raw plastic pellets to finished products. This vertical integration ensures consistent quality, reliability, and flexibility to meet diverse customer needs. Products are shipped across North America, Europe, the Middle East, Latin America, and Australia, serving industries such as water treatment, food & beverage, pharmaceuticals, and industrial/chemical processing.

“As our capabilities have expanded, the name American Filter Manufacturing reflects both who we are today and where we’re headed,” said Fred Geyer, President. “Together with LFH, we’re proud to deliver full-system filtration solutions while investing in new technologies that address tomorrow’s challenges.”

The company’s leadership and ownership remain unchanged. Customers will begin seeing the new AFM name and branding in October 2025.

Media Contact:
Adam Albrecht
Vice President
American Filter Manufacturing Inc.
adam.albrecht@afm.us
www.afm.us

SOURCE: American Filter Manufacturing

View the original press release on ACCESS Newswire

BOCA RATON, FL / ACCESS Newswire / September 25, 2025 / BitBridge Capital Strategies Inc. (OTC:BTTL) (the “BitBridge”), a pioneering American Bitcoin treasury company dedicated to bridging traditional finance with the power of Bitcoin, today announced a multi-year sponsorship agreement with Playfly Sports Properties, the exclusive multimedia rights holder for University of Central Florida (UCF) Athletics. This partnership positions BitBridge as a “Proud Partner of UCF Athletics/Knights,” enhancing visibility and engagement with one of the nation’s most dynamic college sports programs.

The agreement provides BitBridge with a range of high-impact sponsorship opportunities focused on UCF’s football program and broader athletics ecosystem. The Bitcoin Is Life^™ slogan and planned Bitcoin Respect Loan^™ product will be the prominent focus of the campaign. Key elements include:

• Signage and Exposure at Home Football Games: Prominent placement on the Field Level Tunnel, Fascia, and South End Zone displays at each regular-season home game at Acrisure Bounce House; and inclusion in Fan Connect Banner ad rotations with a 30-second commercial spot on select stadium TVs.

• Activation Opportunities: On-site engagement during pre-game festivities in every regular-season home football game, allowing BitBridge to connect directly with fans.

• Digital Presence: Logo placement on the UCF Athletics Corporate Partner page.

This collaboration supports BitBridge’s mission to integrate innovative financial strategies into high-visibility platforms, reaching Knight Nation’s passionate fan base while aligning with UCF’s commitment to excellence in athletics.

“We are thrilled to partner with UCF Athletics, a program that embodies innovation, resilience, and forward-thinking – just like BitBridge,” said Paul Jaber, Executive CEO of BitBridge Capital Strategies. “This sponsorship allows us to engage with a vibrant community that understands both bitcoin and the public markets. We’re excited to charge on with the Knights as we showcase how Bitcoin treasury strategies can empower the future of finance.”

“BitBridge’s forward-looking approach to finance makes them an ideal partner for UCF Athletics,” added Garrett Altier, General Manager of Playfly Sports Properties at UCF. “This agreement not only strengthens our sponsorship portfolio but also brings new energy to our game-day experiences and digital platforms. We are proud to welcome BitBridge to the Knight Nation family.”

About BitBridge Capital Strategies Inc.
BitBridge Capital Strategies is an American Bitcoin treasury company that empowers individuals and institutions to unlock liquidity and protect generational wealth through strategic Bitcoin investments and innovative lending solutions. By allocating its balance sheet primarily to Bitcoin, BitBridge preserves purchasing power and capitalizes on long-term appreciation, while its consumer-facing initiatives promote Bitcoin education and adoption. With a focus on innovative financial strategies, including disruptive Bitcoin lending, and its bold Bitcoin Is Life^™ branding campaign, BitBridge aims to deliver. Headquartered in Boca Raton, Florida, the company expects to begin trading in the late third quarter and will provide market updates as its listing process progresses. Follow us on https://x.com/BitBridgebtc and visit https://bitbridgebtc.com/ or contact investor relations at ir@bitbridgebtc.com.

About UCF Athletics
UCF is a proud member of the Big 12 Conference. Our mission is to positively transform the lives of our students academically, athletically, and personally through a nationally competitive intercollegiate athletics program that enhances the reputation and visibility of the University. We strive to be Florida’s preeminent athletic program representing UCF and our community with distinction on the national stage as “Orlando’s Hometown Team”. To learn more about UCF and Athletics, please visit our websites at www.ucf.edu and www.ucfknights.com.

About Playfly Sports
Playfly Sports is the leading revenue maximizer in the sports industry. Our consultative, data-driven approach to reach, engage, monetize, and measure fandom powers partnerships with premier athletic departments and conferences across the U.S.

Forward-Looking Statements:
This press release contains forward-looking statements based on current expectations and assumptions that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to a variety of factors. These statements are not guarantees of future performance, and BitBridge disclaims any obligation to update them, except as required by law.

Media Contact:
Leah Messina
Director of Communications for BitBridge
Email: leah@sinuatemedia.com
Phone: 917-843-8164

SOURCE: BitBridge Capital Strategies Inc.

View the original press release on ACCESS Newswire

Fully funded to complete construction in Quebec and advance Colombia validation as production and exploration plans at Montauban accelerate

VANCOUVER, BC / ACCESS Newswire / September 25, 2025 / ESGold Corp. (“ESGold” or the “Company”) (CSE:ESAU)(OTCQB:ESAUF)(FSE:Z7D) is pleased to provide a construction update on its Montauban Gold-Silver Project in Quebec, where development is progressing. The Company reports that building construction remains on track, with completion anticipated by mid-Q4 2025. ESGold is fully funded to complete Montauban and is positioned to move forward aggressively, while continuing preparatory work on its prospective initiative in Colombia.

See construction progress photos here

Recent Highlights

• Construction Advancing: Development work at Montauban continues to progress on schedule with building completion anticipated in Q4-2025

• Fully Funded: Recent financing provides all necessary capital to complete Montauban and validate the Company’s Colombia joint venture.

• Upcoming Catalysts: Concentrate test results from both Montauban and Colombia expected in the near-term.

• Exploration Upside: Systematic exploration planning underway at Montauban, technical work has identified large, continuous geological structures extending to 1,200 meters, underscoring the district-scale potential of the property.

• Colombia Momentum: Ongoing review of the Bolívar area reinforces confidence in validating, closing, and executing the Company’s expansion strategy.

Gordon Robb, CEO of ESGold, commented:
“We are extremely pleased with the steady progress at Montauban, where building construction is advancing on schedule and moving toward completion, anticipated by mid-Q4 2025. Thanks to recent funding, we are now in the position of being fully financed to complete Montauban and to advance preparatory work on our prospective initiative in Colombia. With concentrate test results pending and exploration planning underway, the months ahead will be transformative as we build cash flow at Montauban while unlocking long-term discovery potential across our portfolio. ESGold is building the foundation for scalable growth, and we are very excited about what lies ahead.”

Building Momentum at Montauban
Construction at the fully permitted Montauban project continues on track, with infrastructure development and building completion anticipated mid-Q4 2025. The facility is advancing toward readiness for equipment delivery and commissioning, aligning with the Company’s strategy to begin production in 2026.

Thanks to recent funding, ESGold is in a strong financial position to complete Montauban and advance its Colombia joint venture without the necessity of returning to the market for capital. Once the team arrives in Colombia for on-the-ground validation, ESGold will be fully equipped to close and execute.

In parallel with construction, ESGold is advancing exploration at Montauban. Despite over a century of historic mining, the deposit has never been systematically explored. Recent technical work has identified large, continuous geological structures extending to 1,200 meters, underscoring the district-scale potential of the property.

Why This Matters to Investors
This update reinforces ESGold’s unique position as a fully funded, fully permitted, near-term producer with significant exploration upside. Unlike most juniors that rely on continuous dilution, ESGold is advancing toward cash flow in 2026 while systematically unlocking discovery potential. The dual track model of cash flow today and discovery tomorrow positions the Company to deliver sustainable shareholder value through both near term production and long-term growth.

What’s Next

• Concentrate test results for both Montauban and Colombia.

• Colombia validation by ESGold’s technical team, followed by deal closure and execution.

• Comprehensive 3D geological model of Montauban currently in progress, designed to integrate ANT survey results and guide systematic exploration.

• Exploration at Montauban will progress to include systematic drilling to highlight the district-scale significance of the deposit.

ESGold is now fully funded and remains focused on advancing Montauban into production, with cash flow targeted for 2026. The Company’s strategy centers on completing construction at its fully permitted Quebec project, generating high-margin revenue from tailings reprocessing, and using that cash flow to fund systematic exploration across the land package. This disciplined approach minimizes dilution and compounds shareholder value over time. With Montauban as the blueprint, ESGold is building a scalable platform designed to deliver sustainable, long-term value for its shareholders.

Qualified Person Statement
The technical content of this news release has been reviewed and approved by André Gauthier, P.Geo., a Director of ESGold and a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Sampling described herein was conducted for due-diligence screening; independent verification, QA/QC, and systematic work remain outstanding. No mineral resources or reserves are declared.

About ESGold Corp.
ESGold Corp. (CSE: ESAU | OTCQB: ESAUF | FSE: Z7D) is a fully permitted, pre-production gold and silver mining company at the forefront of scalable clean mining and exploration innovation. With proven expertise in Quebec, the Company is advancing its Montauban Gold-Silver Project toward near-term production while unlocking long-term value through strategic redevelopment, modern discovery tools, and sustainable resource recovery. Montauban, located 80 km west of Quebec City, represents a blueprint for cash-flow-generating legacy site redevelopment across North America.

For more information, please contact ESGold Corp. at +1-888-370-1059 or visit esgold.com for additional resources, including a French version of this press release, past news releases, a 3D model of the Montauban processing plant, media interviews, and opinion-editorial pieces.

Stay connected by following us on X (formerly Twitter), LinkedIn, and joining our Telegram channel.

For further information or to connect directly, please reach out to Gordon Robb, CEO of ESGold Corp. at gordon@esgold.com or call 250-217-2321.

On behalf of the Board of Directors
ESGold Corp.
Paul Mastantuono
Chairman & COO
info@esgold.com
+1-888-370-1059

Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements regarding future production, cash flow, exploration results, project economics, and permitting. Forward-looking information is based on reasonable assumptions that management believes are current but involve known and unknown risks and uncertainties that may cause actual results to differ materially. These risks are detailed in the Company’s public filings on SEDAR+. Readers are cautioned not to place undue reliance on such statements. ESGold disclaims any obligation to update or revise any forward-looking information, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

SOURCE: ESGold Corp

View the original press release on ACCESS Newswire

BOCA RATON, FL / ACCESS Newswire / September 25, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today proudly announced that the Company’s live coverage of the Charlie Kirk Remembrance Service from Phoenix delivered record-setting ratings, with over eight million Americans tuning in across its television platforms.

The service, which honored the life and legacy of one of the most influential conservative voices of his generation, resonated deeply with viewers nationwide.

Newsmax’s commitment to delivering meaningful, live coverage of moments that matter was met with an overwhelming response and unprecedented ratings success.

According to Nielsen data and internal streaming metrics:

• 8+ million total viewers watched Newsmax and Newsmax2 combined.

• 6+ million tuned into Newsmax’s cable channel, marking one of the network’s strongest live event performances to date.

• 2+ million streamed on Newsmax2, the network’s fast-growing streaming platform, showcasing Newsmax’s reach beyond traditional television.

• 2.5 million cable viewers were in the key demo A35-64.

• #2 in cable overall; Newsmax ranked just behind Fox News in total audience during coverage.

These results underscore Newsmax’s extraordinary growth and relevance, as Americans increasingly turn away from legacy media outlets in search of unfiltered, balanced coverage.

A National Moment of Remembrance

Charlie Kirk, founder of Turning Point USA, has been a prominent advocate for conservative principles, youth empowerment, and faith-based activism. He was a frequent guest on Newsmax, including during long periods he was banned from appearing on Fox News.

His remembrance service in Phoenix was a solemn yet inspirational gathering, drawing President Trump and the Kirk family, friends, political leaders and supporters from across the country.

Newsmax delivered live, uninterrupted coverage for eight hours, ensuring millions of Americans could take part in honoring Kirk’s contributions. The broadcast highlighted heartfelt tributes, stirring personal stories, and reflections on his enduring impact on conservative thought and grassroots movements.

“Americans are making the switch to Newsmax in historic numbers,” said Christopher Ruddy, CEO of Newsmax. “The overwhelming response to our coverage of the Charlie Kirk Remembrance shows that when a moment matters, people turn to Newsmax. We are proud to provide a platform that honors America’s values, traditions, and leaders like Charlie Kirk. We thank our viewers for placing their trust in us.”

About Newsmax
Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Investor Contacts
Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

Company continues to build momentum and continued positive client growth relative to prior years

VIRGINIA BEACH, VA / ACCESS Newswire / September 25, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., provides a shareholder update highlighting key achievements that represent progress and momentum year to date.

Inspire Veterinary Partners Chairman, CEO, and President Kimball Carr commented, “Inspire is back to growth and we are better positioned for success than ever before. Following our letter to shareholders earlier in 2025, we are very excited to continue to share the progress Inspire is making and how we’re seeing the benefits of our collective work reflected in our business. The company is consistently delivering positive results, new growth across a wide array of measures and KPIs ,and there is maturity in our systems and leadership team, which are delivering results on a daily basis. We’re looking forward to finishing strong in 2025 and springing forward toward increased growth in 2026.”

Accomplishments to date include:

• The highest new client growth in more than a year, with clinics across the portfolio achieving positive new client growth compared to 2024 and prior

• Completion of an enterprise-wide rollout of cloud-based Electric Medical Record (EMR) and Practice Management Software (PMS) across all clinics

• Deployment of Artificial Intelligence (AI)-based transcription for medical notes, enabling enhanced productivity and efficiency across the company’s business units

• Record breaking veterinarian hiring with nine new doctor starts since the beginning of 2025

• Completion of the company’s fifth acquisition in the state of Florida

• Signing of a Letter of Intent for a planned acquisition of the company’s first location in New Jersey, which will be the Company’s 15^th location nationwide

• A return to positive revenue comps as reported in Q2 2025

• Deployment of infrastructure investments including a new talent management system; new engagement, recognition and incentive-based pay structures; new finance professionals and enhancements to the company’s purchase and inventory management systems; new investor relations and investment banking partnerships

Mr. Carr continued, “Having solidified this progress, we now anticipate a strong end to the year, including the closing of our New Jersey acquisition, with several additional acquisition agreements anticipated for year-end and early 2026. We also are developing and preparing to launch new business verticals that will expand our offerings to clients, while simultaneously expanding key facilities across our network to provide broader service offerings and growth in existing clinics. Finally, we are working diligently to enhance our already world-class compensation and benefits plan to add equity offerings for all employees, which we believe will encourage future acquisition and expansion into new geographies. We remain enthusiastic and look forward to working closely with our partners to ensure a bright future for Inspire and look forward to providing updates as our progress continues.”

About Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.

Facebook | LinkedIn | X

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Investor Contact

CORE IR
516-386-0430
investors@inspirevet.com

Press Contact

CORE PR
Matthew Cossel
pr@coreir.com

General Inquires

Morgan Wood
Mwood@inspirevet.com

SOURCE: Inspire Veterinary Partners, Inc.

View the original press release on ACCESS Newswire

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally

SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received notice from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) of a $250,000 grant. Canalevia, under the name Canalevia-CA1, is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs. The grant would support a confirmatory study required for full FDA approval of Canalevia (crofelemer delayed-release tablets) for the treatment of CID in dogs. Acceptance of the award is dependent upon the company’s compliance with FDA terms and conditions. The company has not yet accepted the award.

“When an animal drug receives conditional approval, the CVM requires that a confirmatory trial take place within 5 years to provide the substantial evidence of effectiveness required for full approval of the drug for the indication,” said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar’s Vice President of Preclinical and Nonclinical Studies. “As announced, enrollment has begun in our ongoing full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs. Although we submitted the application for this grant in June 2024, notifications of successful grant awards were delayed due to the new federal administration and funding modifications by the National Institutes of Health. We are planning to request approval from the CVM to use the grant to support this ongoing, slightly modified, field study in dogs undergoing chemotherapy.”

“Looking forward, as announced, Jaguar is in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for the expanded indication of treatment of general diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “Our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; and maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs.”

Dogs undergoing chemotherapy are an important predictive model for crofelemer’s mechanism of action in humans experiencing diarrhea due to cancer treatment. Many cancer treatment agents provided to dogs are human drugs, or have the same mechanism of action as human cancer drugs, and these agents and mechanisms of action often have meaningful rates of diarrhea in humans as well. As announced yesterday, Jaguar family company Napo Pharmaceuticals has submitted an orphan drug designation application to the FDA for crofelemer for the treatment of diarrhea in adult patients receiving targeted therapy, with or without standard chemotherapy, for breast cancer that has metastasized to the brain.

A report by the American Veterinary Medical Foundation concluded that there were approximately 90 million dogs in the U.S. in 2024, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 104 million dogs in Europe in 2022.

Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. Canalevia-CA1, a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy.

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.¹ According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will request approval from the CVM to use the grant to support the company’s ongoing, slightly modified, field study in dogs undergoing chemotherapy, and Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in dogs with general diarrhea. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire